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Abstract
Background: The molecular factors which control circulating levels of inflammatory proteins are not well understood.
Furthermore, association studies between molecular probes and human traits are often performed by linear model-
based methods which may fail to account for complex structure and interrelationships within molecular datasets.
Methods: In this study, we perform genome- and epigenome-wide association studies (GWAS/EWAS) on the levels of
70 plasma-derived inflammatory protein biomarkers in healthy older adults (Lothian Birth Cohort 1936; n = 876; Olink®
inflammation panel). We employ a Bayesian framework (BayesR+) which can account for issues pertaining to data
structure and unknown confounding variables (with sensitivity analyses using ordinary least squares- (OLS) and mixed
model-based approaches).
Results: We identified 13 SNPs associated with 13 proteins (n = 1 SNP each) concordant across OLS and Bayesian
methods. We identified 3 CpG sites spread across 3 proteins (n = 1 CpG each) that were concordant across OLS, mixed-
model and Bayesian analyses. Tagged genetic variants accounted for up to 45% of variance in protein levels (for MCP2,
36% of variance alone attributable to 1 polymorphism). Methylation data accounted for up to 46% of variation in
protein levels (for CXCL10). Up to 66% of variation in protein levels (for VEGFA) was explained using genetic and
epigenetic data combined. We demonstrated putative causal relationships between CD6 and IL18R1 with inflammatory
bowel disease and between IL12B and Crohn’s disease.
Conclusions: Our data may aid understanding of the molecular regulation of the circulating inflammatory proteome
as well as causal relationships between inflammatory mediators and disease.
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Background
Inflammation represents a concerted cascade of molecu-
lar and cellular events to combat infectious pathogens
and endogenous insults. Inflammatory proteins are key
mediators of defence and repair responses, and tight
spatiotemporal regulation of their plasma concentrations
permits effective immune activation and resolution [1].
Whereas acute inflammatory states may prompt severe
illness and death, absence of resolution precipitates tran-
sition from acute to deleterious chronic inflammatory
states [2]. Chronic inflammation facilitates the pathogen-
esis of various disease states, including diabetes, heart
disease, stroke and allergic conditions [3]. Furthermore,
inflammatory lesions in brain tissue are often associated
with, and may contribute to, neurodegeneration and
cognitive decline [4]. Globally, 60% of individuals will
die as a consequence of a chronic inflammation-
associated disease state [5]. Therefore, identifying bio-
logical factors which govern inter-individual variation in
circulating inflammatory protein levels may allow for
better prediction of individual disease risk and prognosis,
and inform disease biology.
To date, a number of studies have aimed to character-
ise genetic factors associated with the levels of single in-
flammatory proteins or a small number of such proteins,
including C-reactive protein, fibrinogen and interleukin-
6 [6–25]. These genetic factors are also known as pro-
tein quantitative trait loci or pQTLs. Additionally, stud-
ies have examined the genetic architecture of panels of
proteins, including inflammatory mediators, and have in-
vestigated co-regulatory pathways and associations with
disease states [26–35]. Instead of using imputed geno-
type data, Höglund et al. used whole genome sequencing
data to carry out genome-wide association studies
(GWAS) on the levels of 72 inflammatory proteins. This
led to the identification of 18 novel loci that were not
identified using genotyped or imputed SNPs [36]. A
number of studies have also carried out epigenome-wide
association studies (EWAS) on the levels of a small set
of inflammatory proteins, including C-reactive protein,
interleukins-(1β, 4, 6, 9 and 10), interferon-gamma,
transforming growth factor-beta and tumour necrosis
factor [37–42]. Zaghlool et al. performed an EWAS of
1123 proteins, which pointed towards networks of
chronic low-grade inflammatory biomarkers (n = 944 in-
dividuals) [43]. In an integrative approach, Ahsan et al.
aimed to identify genetic and epigenetic markers associ-
ated with protein biomarkers including inflammatory
mediators (n ≤ 1033 individuals) [44]. No study has mod-
elled GWAS and EWAS both as stand-alone association
studies and in a combined analysis in the context of
proteomic data. This would allow for the identification
of genetic and epigenetic correlates of inflammatory pro-
tein levels and for the estimation of variance in protein
levels explained by genetic and epigenetic data, consid-
ered in isolation but also conditioned on one another to
reflect reciprocal influences of these molecular data
types. Here, we triangulate results from multiple statis-
tical approaches to provide a robust set of genetic and
epigenetic correlates of inflammatory protein levels.
Notably, most studies examining the molecular archi-
tecture of human traits have relied on linear model-
based methods which examine marker or probe effects
marginally [45, 46]. A number of issues may arise when
using linear regression-based methods and if these are
not addressed in the study design, it may lead to model
overfitting and biased estimation of effect sizes. These
potential issues include correlation structure within mo-
lecular datasets, data structure (i.e. cellular heterogen-
eity, batch effects) and omitted variable bias [47]. Several
approaches have been proposed to address these issues
[47–53] and these encompass strategies which permit
the joint and conditional estimation of effect sizes whilst
accounting for correlations among markers and con-
founding variables. Here, we consider a Bayesian pena-
lised regression framework termed BayesR+ which was
developed to assess genetic and epigenetic architectures
of complex traits [54]. In BayesR+, marker effects
(SNP or CpG site) can be estimated jointly whilst con-
trolling for data structure and correlations among mo-
lecular markers of different types. Indeed, this method
permits the estimation of variance explained in the trait
by all methylation probes or genetic markers, either sep-
arately or together. BayesR+ has been shown to outper-
form single-probe linear regression and penalised
regression approaches, such as ridge and LASSO, in rela-
tion to the correlation of estimated effects with true sim-
ulated values as well as mean squared errors between
true and estimated coefficients for single-probe regres-
sion. Additionally, BayesR+ shows a higher correlation
between estimated effects for variance explained by gen-
etic and epigenetic markers in phenotypic traits and true
simulated values when compared to a mixed model
strategy in both sparse and non-sparse marker settings
[54].
In the present study, we use the BayesR+ method (and
sensitivity analyses using ordinary least squares (OLS)
[55, 56] and mixed model methods [57]) to examine
both the genetic and epigenetic architectures of 70 blood
inflammatory proteins in 876 relatively healthy older
adults from the Lothian Birth Cohort 1936 study (mean
age 69.8 ± 0.8 years; levels adjusted for age, sex, popula-
tion structure and array plate). Hereinafter, we refer to
the adjusted inflammatory protein levels as protein
levels. These proteins are present on the Olink® inflam-
mation panel and comprise a mixture of proteins with
defined functions pertinent to human inflammatory
pathways as well as putative roles in inflammation-
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related disease states. We use priors guided by results
from previous genome-wide and epigenome-wide studies
[54, 58] for the expected variance explained in circulat-
ing protein levels by genetic and epigenetic factors. Ap-
plying a stringent approach, we only consider markers
or probes that were identified across all methods
employed as being associated with a given protein (con-
cordantly identified) and integrate multiple levels of
‘omics’ data to investigate mechanisms by which genetic
variants may influence protein levels. Finally, we use our
GWAS summary data to test for putatively causal rela-
tionships between inflammatory protein biomarkers and
neurological or inflammatory disease states. Thus, this
paper has two major aims. The first aim is to provide ro-
bust and novel estimates for the contribution of genetic
and epigenetic factors towards inter-individual variation
in circulating inflammatory protein concentrations. The
relationships between genetic and epigenetic factors with
inflammatory proteins levels are modelled both alone
and together. The second aim is to provide the first use
of multiple statistical methods in performing genome-
wide and epigenome-wide association studies of human
proteomic data.
Methods
The Lothian Birth Cohort 1936
The Lothian Birth Cohort 1936 (LBC1936) study is a
longitudinal study of ageing. Cohort members were all
born in 1936 and most took part in the Scottish Mental
Survey 1947 at age 11 years. Participants who were living
mostly within the Edinburgh area were re-contacted ap-
proximately 60 years later (n = 1091, recruited at mean
age 70 years). Recruitment and testing of the LBC1936
cohort have been described previously [59, 60].
Protein measurements in the Lothian Birth Cohort 1936
Plasma was extracted from 1047 blood samples and col-
lected in lithium heparin tubes at mean age 69.8 ± 0.8
years. Following quality control, 1017 samples remained.
Plasma samples were analysed using a 92-plex proximity
extension assay (Olink® Bioscience, Uppsala Sweden).
One protein from the panel, BDNF, failed quality control
and was removed from the study. For a further 21 pro-
teins, over 40% of samples fell below the lowest limit of
detection. These proteins were removed from analyses
leaving a final set of 70 proteins. The proteins assayed
comprise the Olink® inflammatory biomarker panel.
Briefly, 1 μL of sample was incubated in the presence of
proximity antibody pairs linked to DNA reporter mole-
cules. Upon appropriate antigen-antibody recognition,
the DNA tails form an amplicon by proximity extension
which is quantified by real-time PCR. Data pre-
processing was performed by Olink® using NPX Manager
software. Protein levels were transformed by rank-based
inverse normalisation and regressed onto age, sex, four
genetic principal components of ancestry and array
plate. Standardised residuals from these regression
models were brought forward for all genetic-protein and
epigenetic-protein analyses. Pre-adjusted protein level
distributions are presented in Additional file 1. Associa-
tions between pre-adjusted protein levels and biological
as well as technical covariates are detailed in Add-
itional file 2: Table S1.
Genome-wide association studies
LBC1936 DNA samples were genotyped at the Edin-
burgh Clinical Research Facility using the Illumina 610-
Quadv1 array (n = 1005; mean age 69.6 ± 0.8 years; San
Diego). Quality control procedures for genetic data are
detailed in Additional file 3.
BayesR+ is a software implemented in C++ for per-
forming Bayesian penalised regression on complex traits
[54]. The joint and conditional effects of typed SNPs
(n = 521,523 variants) on transformed protein levels were
examined. The prior distribution is specified as a mix-
ture of Gaussian distributions, corresponding to effect
sizes of different magnitude, and a discrete spike at zero
which enables the omission of probes and markers with
negligible effect on the phenotype. Informed by data
from our previous pQTL study [58], mixture variances
for genetic data were set to 0.01 and 0.1 for the stand-
alone BayesR+ GWAS. In the combined analysis with
epigenetic data, owing to the need for the same number
of mixture variances for genetic and epigenetic data in
the BayesR+ software, mixture variances were set to
0.01, 0.1 and 0.2. Input data were scaled to mean zero
and unit variance, and adjusted for age and sex. To ob-
tain estimates of effect sizes, Gibbs sampling was used to
sample over the posterior distribution conditional on the
input data. The Gibbs algorithm consisted of 10000 sam-
ples and 5000 samples of burn-in after which a thinning
of 5 samples was utilised to reduce autocorrelation. Gen-
etic markers which exhibited a posterior inclusion prob-
ability of ≥ 95% were deemed to be significant.
Details for the OLS regression model approach are
outlined in Additional file 3. In the linear method,
markers which surpassed a Bonferroni-corrected condi-
tional significance threshold of 7.14 × 10−10 (= genome-
wide significance 5.0 × 10−8/70 phenotypes) were consid-
ered. The genome-wide significance level of 5.0 × 10−8
was selected as per convention in GWAS studies.
Epigenome-wide association studies
DNA from whole blood was assessed using the Infinium
450 K methylation array at the Edinburgh Clinical Re-
search Facility (n = 876; mean age 69.8 ± 0.8 years). Qual-
ity control procedures for methylation data are detailed
in Additional file 3.
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Using BayesR+, prior mixture variances for methyla-
tion data (n = 459,309 CpG sites) were set to 0.001, 0.01
and 0.1. Age, sex and Houseman-estimated white blood
cell proportions [61] were incorporated as fixed effect
covariates. The same settings as in the genetic analyses
were applied. Methylation probes which had a posterior
inclusion probability of ≥ 95% were deemed to be
significant.
Details for the OLS and mixed linear model ap-
proaches are outlined in Additional file 3. For these
methods, probes which surpassed a Bonferroni-corrected
significance threshold of 5.14 × 10−10 (= genome-wide
significance 3.6 × 10−8/70 phenotypes) were deemed to
be significant. The genome-wide significance level of
3.6 × 10−8 was selected as per the recommendations of
Safarri et al. [62].
Functional annotation of genetic and epigenetic loci
Genetic markers that were independently associated with
protein levels were functionally annotated using ANNO-
VAR [63] and Ensembl genes (build 85) in FUMA (FUnc-
tional Mapping and Annotation) [64]. Epigenetic probes
associated with protein levels were annotated using the
IlluminaHumanMethylation450kanno.ilmn12.hg19 pack-
age [65].
Identification of overlap between cis pQTLs and cis eQTLs
To determine whether pQTL variants may affect protein
levels through modulation of gene expression, we cross-
referenced cis pQTLs with publicly available (and FDR-
corrected significant) cis expression QTL (eQTL) data
from the eQTLGen consortium. Expression QTL data
were derived from blood tissue, 85% of samples were de-
rived from whole blood and 15% of samples were de-
rived from peripheral blood mononuclear cell data [66].
For each protein, expression QTLs were also subset to
the gene (messenger RNA) encoding the protein of
interest.
Colocalisation
To test whether a sole causal variant might underlie
both an eQTL and pQTL association, we performed
Bayesian tests of colocalisation using the coloc pack-
age in R [67]. For each protein of interest, a 200-kb
region (upstream and downstream—recommended
default setting) surrounding the appropriate pQTL
was extracted from our GWAS summary statistics
[68]. For each respective protein, the same region
was also extracted from eQTLGen summary statis-
tics. Default priors were applied. Summary statistics
for all SNPs within these regions were used to deter-
mine the posterior probability for five distinct hy-
potheses: a single causal variant for both traits, no
causal variant for either trait, a causal variant for
one of the traits (encompassing two hypotheses), or
distinct causal variants for the two traits. Posterior
probabilities (PP) ≥ 0.95 provided strong evidence in
favour of a given hypothesis.
Pathway enrichment and tissue specificity analyses
Using methylation data, pathway enrichment was
assessed among KEGG pathways and Gene Ontology
(GO) terms through hypergeometric tests using the phy-
per function in R. All gene symbols from the 450 K array
annotation (null set of sites) were converted to Entrez
IDs using biomaRt [69, 70]. GO terms and their corre-
sponding gene sets were retrieved from the Molecular
Signatures Database (MSigDB)-C5 [71]. KEGG pathways
were downloaded from the KEGG REST server [72]. Tis-
sue specificity analyses were performed using the GEN-
E2FUNC function in FUMA. Differentially expressed
gene sets with Bonferroni-corrected P values < 0.05 and
an absolute log-fold change of ≥ 0.58 (default settings)
were considered to be enriched in a given tissue type
(GTEx v7).
Mendelian randomisation
Two-sample Mendelian randomisation was used to test
for putatively causal relationships between (i) the 4 pro-
teins whose pQTLs were previously shown to be associ-
ated with human traits, as identified through GWAS
Catalog, and the respective traits [73, 74] (http://www.
nealelab.is/uk-biobank/); (ii) the 13 proteins which har-
boured significant pQTLs and Alzheimer’s disease risk
[75]; (iii) gene expression and inflammatory protein
levels; and (iv) DNA methylation and inflammatory pro-
tein levels. Pruned variants (LD r2 < 0.1) were used as in-
strumental variables (IV) in MR analyses. In tests where
only one independent SNP remained after LD pruning,
causal effect estimates were assessed using the Wald ra-
tio test, i.e. a ratio of effect per risk allele on trait to ef-
fect per risk allele on protein levels. In tests where
multiple independent variants were identified, and if no
evidence of directional pleiotropy was present (non-sig-
nificant MR-Egger intercept), multi-SNP MR was carried
out using inverse variance-weighted estimates. Analyses
were conducted using MRbase [76]. Further details are
provided in Additional file 3.
Results
Genome-wide studies of inflammatory protein levels
In a Bayesian penalised regression model (BayesR+), 16
pQTLs were identified for 14 proteins (Additional file 2:
Table S2). Thirteen of these 16 pQTLs (n = 13 proteins)
directly, or through variants in high linkage disequilib-
rium (LD) r2 > 0.75, replicated conditionally significant
pQTLs from the OLS regression model (Additional file
2: Tables S3-S5; Additional file 3). The correlation
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structure among these 13 proteins is shown in Add-
itional file 4: Fig. S1.
Twelve (92.3%) of the concordant SNPs were cis
pQTLs (SNP within 10Mb of the transcription start site
(TSS) of a given gene [69, 70]) and 1 pQTL (7.7%) was a
trans-associated variant (Fig. 1a; Additional file 2: Table
S6). There was an inverse relationship between the
minor allele frequency of variants and their effect size
(Fig. 1b). The functional category to which the greatest
proportion of variants was assigned was exonic variants
(38.5%), as identified by FUMA (FUnctional Mapping
and Annotation analysis) (Fig. 1c). Four of the five SNPs
Fig. 1 Genetic architecture of inflammatory protein biomarkers in the Lothian Birth Cohort 1936. a Chromosomal locations of pQTLs concordant between
Bayesian penalised and ordinary least squares regression models for genome-wide association studies (n=13 pQTLs). The x-axis represents the chromosomal
location of concordantly identified cis and trans SNPs associated with the levels of Olink® inflammatory proteins. The y-axis represents the position of the gene
encoding the associated protein. The sole conditionally significant concordant trans association is annotated. Cis (red circles); trans (blue circles). b Absolute
effect size (per standard deviation of difference in protein level per effect allele) of pQTLs versus minor allele frequency. Cis (red circles); trans (blue circles). c
Classification of 13 pQTLs by function as defined by functional enrichment analysis in FUMA. d Variance in protein levels explained by pQTLs (estimates from
Bayesian penalised regression are displayed)
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annotated to exonic regions produce missense muta-
tions. From the Bayesian model, pQTLs explained be-
tween 5.28% (rs10005565; CXCL6) and 35.80%
(rs3138036; MCP2) of inter-individual variation in pro-
tein levels (Fig. 1d). The estimates for variance
accounted for in protein levels by single SNPs were cor-
related 99% between the BayesR+ and OLS regression
models (Fig. 2a; Additional file 2: Table S6). The
BayesR+ common (minor allele frequency > 1%) SNP-
based heritability estimates ranged from 11.4% (CXCL9;
95% credible interval [0%, 43.5%]) to 45.3% (MCP2; 95%
credible interval: [23.5%, 70.6%]), with a mean estimate
of 20.2% across the 70 proteins (Additional file 2: Table
S7). Figure 2b shows heritability estimates for the 13
proteins exhibiting concordantly identified pQTLs across
OLS regression and Bayesian approaches. Figure 3 dem-
onstrates the effect of genetic variation at the most sig-
nificant cis pQTL (rs3138036; MCP2) and the sole trans
pQTL (rs12075; MCP4) on protein levels.
There was a strong correlation between our SNP-
based heritability estimates and those from a previous
study of 961 individuals [44]: 29 overlapping proteins, r
0.71, 95% CI [0.43, 0.84] (Additional file 2: Table S8 and
Additional file 4: Fig. S2).
Molecular mechanisms underlying pQTLs: colocalisation
analysis
Of the 12 cis pQTLs which were identified across OLS
regression and BayesR+, 8 SNPs (66.67%) previously
have been identified as cis-acting expression QTLs
(eQTLs) in blood (Additional file 2: Table S9). Using
coloc [67], we tested the hypothesis that one causal vari-
ant might underlie both a pQTL and eQTL for each
protein. For 4/8 proteins, there was strong evidence
(posterior probability (PP) > 0.95) for colocalisation of cis
pQTLs and cis eQTLs (Additional file 2: Table S10).
These proteins were CCL25, CD6, CXCL5 and CXCL6.
Fig. 2 Variance in circulating inflammatory protein levels explained by common genetic variation. a In this panel, the variance explained (r2) by
consensus SNPs (n = 13 SNP, 1 per protein) in the ordinary least squares regression model was compared against the variance explained by the
same SNP set identified in the Bayesian penalised regression approach. b The proportion of variance explained in Olink® inflammatory protein
levels by common genetic variants genotyped in the LBC1936 participants is shown. Only those proteins which had significant pQTL associations
in both the ordinary least squares and Bayesian methods are presented (n = 13). Additionally, the proportion of variance explained attributable to
medium effects (prior: variance of 1% explained) and large effects (prior: variance of 10% explained) are demonstrated in purple and green,
respectively. Error bars represent 95% credible intervals
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Mendelian randomisation analyses (MR; see the
‘Methods’ section) indicated that altered gene expression
was causally associated with changes in protein levels for
each of the four aforementioned proteins (CCL25, CD6,
CXCL5 and CXCL6; range of beta [0.68, 12.25], se [0.09,
1.12], P [9.54 × 10−7, 1.05 × 10−37]). However, a second
colocalisation approach termed Sherlock [77] suggested
that, from the 13 proteins with concordantly identified
pQTLs, only expression of ADA, CXCL5 and IL18R1
were associated with levels of their respective protein
products (Additional file 2: Table S11; Additional file 3).
Epigenome-wide studies of inflammatory protein levels
In the Bayesian model, 8 CpG-protein associations (n = 8
proteins) had a posterior inclusion probability of more
than 95% (Additional file 2: Table S12). Five of these asso-
ciations overlapped with those identified by the OLS re-
gression model (P < 5.14 × 10−10; Additional file 2: Table
S13); three of which were also identified in the mixed
model approach (P < 5.14 × 10−10; Additional file 2: Table
S14). These were the smoking-associated probe
cg05575921 for CCL11 levels (trans association at AHRR;
mixed model—beta − 1.97, se 0.32, P 4.86 × 10−10),
cg07839457 for CXCL9 levels (trans association at
NLRC5; beta − 2.91, se 0.39, P 8.03 × 10−14 ) and
cg03938978 for IL18R1 levels (cis association at IL18RAP;
beta − 1.37, se 0.16, P 5.86 × 10−17) (Additional file 2:
Table S14). Adjustment for smoking attenuated the asso-
ciation between CCL11 levels and the cg05575921 probe
(linear model—before adjustment: beta − 1.74, P 2.68 ×
10−10, after adjustment: beta − 1.20, P 0.03; % attenuation
31.03%). GWAS and EWAS of CCL11 levels were re-
peated adjusting for smoking status, the results of the as-
sociation studies are detailed in Additional file 3. Figure 4
depicts an epigenetic map of CpG-protein associations
within this study and demonstrates the degree of overlap
between methodologies. The correlation among the three
proteins with concordantly identified CpG associations is
shown in Additional file 4: Fig. S3. Look-up analyses of
the top GWAS and EWAS findings with those reported in
the literature are detailed in Additional file 3. For the
GWAS, 11/13 pQTLs (84.62%) from the present study
were previously reported in the literature. The two loci
which represent novel pQTLs are rs11700291 (ADA) and
rs1458038 (FGF-5). Beta coefficients displayed a correl-
ation coefficient of 0.88 between those in the present
study and those reported in previous studies. For the
EWAS, only one of the three concordantly identified
Fig. 3 Effect of genetic variation on inflammatory protein levels. a Box plot of MCP2 levels as a function of genotype (rs3138036, effect allele: G,
other allele: A, beta = − 1.20, se = 0.06). b Box plot of MCP4 levels as a function of genotype (rs14075, effect allele: G, other allele: A, beta = − 0.62,
se = 0.05). Centre line of boxplot: median, bounds of box: first and third quartiles
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CpG-protein associations was previously reported in the
literature by Ahsan et al. [44]. This association was be-
tween the cg07839457 probe (NLRC5) and CXCL9 levels
(betaLBC − 2.91 vs. betaAhsan − 3.26).
We conducted tissue specificity and pathway enrichment
analyses based on genes identified by EWAS for each of the
3 proteins with significant CpG associations. Tissue-specific
patterns of expression were observed for 2/3 proteins (Add-
itional file 4: Fig. S4-S6). For CCL11, differential expression
was observed in breast, adipose and kidney tissue. For
IL18R1, differential expression of associated genes was ob-
served in pancreatic tissue. Furthermore, down-regulation of
genes associated with IL18R1 was observed in the hippocam-
pus and substantia nigra. There was no significant enrich-
ment of pathways incorporating genes annotated to CXCL9,
CCL11 or IL18R1 following multiple testing correction.
One protein, IL18R1, harboured both a significant cis
pQTL and cis CpG site in our study (Additional file 4:
Fig. S7). This SNP (rs917997) previously has been identi-
fied as a methylation QTL (mQTL) for the single cis
CpG site associated with IL18R1 levels identified by our
epigenome-wide studies (cg03938978) [78]. Using bidir-
ectional MR analysis (Wald ratio test; see methods), we
show evidence that DNA methylation at this locus may
be causally associated with circulating IL18R1 levels
(beta − 0.81, se 0.17, P 2.14 × 10−33). Conversely, IL18R1
levels may also be causally associated with altered DNA
methylation (beta − 1.22, se 0.16, P 3.4 × 10−14).
The methylation data explained an average of 18.2% of
variance in protein levels using BayesR+; estimates
ranged from 6.3% (IL15RA, 95% credible interval [0.0%,
27.3%]) to 46.1% (CXCL10, 95% credible interval [24.1%,
Fig. 4 Genomic locations of CpG sites associated with differential inflammatory protein levels. The x-axis represents the chromosomal location of
CpG sites associated with the levels of Olink® inflammation biomarkers. The y-axis represents the position of the gene encoding the associated
protein. The level of concordance across three models used to perform epigenome-wide association studies is represented by different shape
patterns. Those CpG sites (n = 3) which were identified by linear (ordinary least squares), mixed model and Bayesian penalised regression models,
and passed a Bonferroni-corrected significance threshold are represented by diamonds and annotated. Three proteins (CXCL9, CXCL10 and
CXCL11) were associated with differential methylation levels at the cg07839457 site in the NLRC5 transcription factor locus. Additionally, two
proteins (CCL11 and TGF-alpha) were associated with the smoking-associated cg05575921 site in the AHRR locus. Cis (red); trans (blue)
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67.1%]) (Additional file 2: Table S15). There was strong
concordance with estimates from the mixed model sen-
sitivity analysis (Additional file 2: Table S16 and Fig. 5a).
Figure 5b shows the variance explained by methylation
data for the 3 proteins exhibiting concordantly identified
CpGs across OLS regression, mixed-model and Bayesian
approaches.
Variation in inflammatory protein levels explained by
genetics and DNA methylation
When accounting for genetic data, the estimates for vari-
ance explained by methylation data were largely un-
changed for most proteins (Additional file 2: Table S17;
n = 9 proteins with change > 5%, 1 with change < − 5%
(VEGFA)). The mean absolute change was 2.6% (mini-
mum 0.01% for TNFRSF9 and maximum 15.0% for
IL18R1). Similarly, estimates from genetic data were
largely unchanged in the combined analysis (n = 2 pro-
teins with change > 5%). The mean absolute change was
1.8% (minimum 0.02% for CD244 and maximum 6.7%
for CCL28). For 22 proteins, the variance explained by
methylation data was greater than that explained by gen-
etic data (Additional file 5).
For each protein, we performed t-tests to determine
whether the variance explained by methylation or gen-
etic data alone was significantly different from the esti-
mate for variance explained in the combined analysis.
For methylation data, 40 proteins showed a significant
difference between the estimates for variance in protein
levels explained by methylation data alone and methyla-
tion data conditional on SNPs (P < 0.05). For genetic
data, 50 proteins showed a significant difference (P <
0.05) (Additional file 2: Table S17).
The combined estimate for variance explained by gen-
etic and methylation data ranged from 23.4% for CXCL1
to 66.4% for VEGFA. The mean and median estimates
were 37.7 and 36.0%, respectively. Details of which SNPs
and CpGs were identified as being associated with pro-
tein levels in the combined BayesR+ analyses, accounting
for all genetic and epigenetic factors together, is outlined
in Additional file 2: Table S18 and Additional file 3.
Evaluating causal associations between inflammatory
biomarkers and human traits
The 13 independent pQTL associations were queried
against GWAS Catalog to identify existing associations
Fig. 5 Variance in circulating inflammatory protein levels explained by DNA methylation. a In this panel, the variance explained in circulating
protein levels by complete methylation data from sites present on the Infinium 450 K methylation array was examined. A comparison between
variance explained (h2) by a mixed model approach (OSCA) and a Bayesian penalised regression approach (BayesR+) is shown. b The proportion
of variance explained in Olink® inflammatory protein levels by DNA methylation, as estimated by BayesR+ is shown. Only those proteins (n = 3)
which had significant CpG associations in ordinary least squares, mixed model and Bayesian methods are presented. Additionally, the proportion
of variance explained attributable to small effects (prior: variance of 0.1% explained), medium effects (prior: variance of 1.0% explained) and large
effects (prior: variance of 10% explained) are demonstrated in blue, gold and dark orange, respectively. Error bars represent 95% credible intervals
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between these pQTLs and phenotypes [73]. We investi-
gated whether these associations represented causal rela-
tionships. Using two-sample MR, we showed that CD6
levels were causally associated with inflammatory bowel
disease (IBD) (beta 0.20, se 0.04, P 2.59 × 10−6). Further-
more, FGF-5 levels were causally associated with systolic
and diastolic blood pressure (beta 0.07 and 0.07, se 0.01
and 0.01, P 1.04 × 10−34 and 4.29 × 10−42, respectively).
IL12B levels were associated with Crohn’s disease (beta
0.42, se 0.05, P 2.76 × 10−15). Circulating IL18R1 levels
showed a causal relationship with IBD (beta 0.17, se
0.03, P 1.63 × 10−9).
Peripheral inflammatory processes and proteins have
been linked to risk of late-onset Alzheimer’s disease
(AD) [79, 80]. We tested whether the 13 proteins with
significant genetic correlates in our study were causally
associated with AD risk (Additional file 3). One protein,
IL18R1, showed a nominally significant, unidirectional
relationship with AD risk (beta 0.02, se 0.01, P 0.04)
(Additional file 2: Table S19).
Discussion
Using a Bayesian framework and sensitivity analyses with
OLS regression and mixed linear models, we robustly
identified 13 independent genetic and 3 epigenetic cor-
relates of circulating inflammatory protein levels. Two of
these pQTLs and two CpG sites have not been previ-
ously reported as genome-wide significant in the litera-
ture. This is the first study to have integrated genetic
and epigenetic data together using multiple methods to
identify molecular correlates of, and estimate the contri-
bution of these molecular factors towards inter-
individual variability in, the circulating proteome. Our
results also provide an important and novel demonstra-
tion of the overlap between disparate methodologies for
performing genome-wide and epigenome-wide associ-
ation studies on proteomic data. Using integrative causal
frameworks, we identified mechanisms through which
genetic variation may perturb plasma protein levels.
Additionally, we demonstrated causal relationships be-
tween prioritised circulating inflammatory proteins and
blood pressure as well as inflammatory bowel diseases.
For genome-wide association studies, there is a neces-
sity to perform secondary analyses in order to identify
independent loci from association studies. This is often
carried out through employing conditional and joint
analyses (GCTA-COJO) or LD clumping-based methods,
such as those implemented in FUMA [54, 64]. BayesR+
negates the need for such secondary analyses; it allows
for the modelling of single marker or probe effects
whilst controlling for all other markers or probes. In-
deed, BayesR+ can outperform OLS regression or mixed
model methods in providing single probe or marker co-
efficient estimates whilst controlling for all other input
SNP and/or CpG sites, as well as known and unknown
confounding variables. However, identifying true mo-
lecular correlates of protein data over false positive asso-
ciations is challenging. By relying on careful corrections
for multiple testing and triangulation of evidence across
disparate methods, our stringent approach was well-
equipped to identify likely true biological signal as op-
posed to false positives.
The issue of identifying true biological signals over
false positive associations is particularly pertinent in re-
lation to trans associations which show poor replication
and often have smaller effect sizes than cis associations
[81]. We identified one trans pQTL (rs12075) associated
with levels of the chemokine MCP4 (encoded for by
CCL13 gene on chromosome 17). This SNP represents a
nonsynonymous polymorphism (Asp42Gly) annotated to
the Duffy antigen/chemokine receptor (DARC) gene on
chromosome 1. Previously, this SNP has been associated
with lower MCP1 levels and evidence shows that the
base-change results in altered chemokine-receptor bind-
ing [10, 20, 82]. Additionally, this polymorphism has
been shown to explain approximately 20% of variation in
MCP1 levels, similar to our estimate of 18.66% in MCP4
levels [82]. The Duffy antigen receptor is expressed on
erythrocytes and acts as a reservoir for circulating che-
mokines resulting in reduced distribution of chemokines
to extravascular tissue and dampened pro-inflammatory
effects [83]. Our findings suggest that this polymorphism
may also lead to reduced MCP4 levels, possibly through
augmented chemokine-receptor interaction.
In the EWAS analyses, the probe cg05575921, located
in the AHRR locus, was associated with CCL11 levels.
This probe is strongly associated with smoking status
[84–91] and the association was attenuated after adjust-
ment for smoking. Furthermore, higher levels of CCL11
have been associated with tobacco smoking and cannabis
use [92–94]. We also found altered methylation at the
NLRC5 locus (NOD-like receptor family CARD domain
containing 5) is associated with circulating CXCL9
levels. NLRC5 acts as a potent regulator of the inflam-
masome [44, 95]. Zaghlool et al. showed that altered
methylation at the NLRC5 locus associates with several
inflammatory markers, including CXCL10 and CXCL11,
with pathway analyses linking it to disease states in
which NLRC5 dysfunction is implicated such as cancer
and cardiovascular disease [43].
Using our database of genotype-protein associations, we
tested for causal relationships between inflammatory pro-
tein biomarkers and human phenotypes. However, in each
case, only one variant was available to test for such associ-
ations which does not allow for the testing of pleiotropic
effects. CD6 was associated with clinically diagnosed IBD.
Expression of the CD6 receptor and its ligand, ALCAM,
are overexpressed in the intestinal mucosa of IBD patients
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where it may promote CD4+ T cell proliferation and dif-
ferentiation into pro-inflammatory Th1/Th17 cells [96].
FGF-5 levels were associated with automated readings of
systolic and diastolic pressure; previously, FGF-5 levels
have been significantly correlated with blood pressure
[97]. Variation in the IL12B gene has been linked strongly
to the pathogenesis of Crohn’s disease and an antibody
targeted towards the p40 subunit of IL12 demonstrated ef-
ficacy in the treatment of moderate-to-severe Crohn’s dis-
ease [98]. In our study, we showed that circulating IL12B
levels may be causally linked to this disease. Lastly,
IL18R1 levels may also be causally associated with IBD. A
number of studies have demonstrated that increased IL18
signalling confers detrimental effects in the context of
gastrointestinal inflammatory processes [99].
Our study has a number of caveats. First, proteins with
high sequence homology and structural similarities to a
targeted protein of interest may be inappropriately cap-
tured by assay probes resulting in quantification errors.
Olink®’s Proximity Extension Assay technology uses a
matched pair of antibodies, coupled to unique, partially
complementary oligonucleotides resulting in exceptional
readout specificity and greatly reducing this problem
compared to other immunoassays. Second, there was a
strong correlation structure among the inflammatory
protein panel. However, given that inflammatory pro-
teins are often co-expressed and synergistic, overlapping
loci may reveal biologically important foci or nodes of
co-regulation [100]. Third, functional enrichment ana-
lyses indicated that four robustly identified pQTL signals
reflect missense mutations in their protein products,
three of which were cis associations with proteins
present on the Olink® inflammation panel. This may lead
to altered structural properties of the protein target,
thereby affecting antibody-antigen recognition and the
ability of assays to accurately quantify protein levels. It is
possible that the variants identified may not reflect vari-
ants causally associated with blood protein levels, and
instead capture a causal variant in the locus. Neverthe-
less, the identification of such potential protein-altering
variants is an important technical consideration in stud-
ies aiming to determine the molecular architecture of
the human proteome. Furthermore, these variants reflect
important candidates for functional characterisation in
in vitro studies which aim to dissect their influence on
protein abundance in cellular systems. Fourth, our Scot-
tish cohort contains individuals from a homogenous
genetic background limiting the generalisability of our
findings to individuals of other ethnic backgrounds.
Fifth, ageing is closely linked to chronic low-grade in-
flammation. Therefore, the distributions of, and correl-
ation structure among, inflammatory protein biomarkers
may differ in our cohort of healthy older ageing when
compared to other age ranges and the general older
adult population. Sixth, the sample size within our study
resulted in large confidence and credible intervals in the
reported estimates for heritabilities in inflammatory pro-
tein levels.
Conclusions
Our integrative and multi-method approach has identi-
fied high-confidence genetic and epigenetic loci associ-
ated with inflammatory protein biomarker levels.
Furthermore, we have provided novel estimates for the
contribution of common genetic and epigenetic variation
towards differences in circulating inflammatory bio-
marker levels, considered alone and together. Together,
our data may have important implications for informing
the molecular regulation of the human proteome. Our
data provides a platform upon which other researchers
may investigate relationships between inflammatory bio-
markers and disease, and a resource to further inform
biological insights into immunological and inflammatory
processes.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13073-020-00754-1.
Additional file 1. Distribution of raw values for inflammatory protein
levels across individuals in Lothian Birth Cohort 1936.
Additional file 2: Supplementary Tables. The association of pre-
adjusted protein levels with biological and technical covariates. Protein
levels were adjusted for age, sex, array plate and four genetic principal
components (population structure) prior to analyses. Significant associa-
tions are emboldened. (Table S1). pQTLs associated with inflammatory
biomarker levels from Bayesian penalised regression model (Posterior In-
clusion Probability > 95%). (Table S2). All pQTLs associated with inflam-
matory biomarker levels from ordinary least squares regression model
(P < 7.14 × 10− 10). (Table S3). Summary of lambda values relating to or-
dinary least squares GWAS and EWAS performed on inflammatory protein
levels (n = 70) in Lothian Birth Cohort 1936 study. (Table S4). Condition-
ally significant pQTLs associated with inflammatory biomarker levels from
ordinary least squares regression model (P < 7.14 × 10− 10). (Table S5).
Comparison of variance explained by ordinary least squares and Bayesian
penalised regression models for concordantly identified SNPs. (Table S6).
Estimate of heritability for blood protein levels as well as proportion of
variance explained attributable to different prior mixtures. (Table S7).
Comparison of heritability estimates from Ahsan et al. (maximum likeli-
hood) and Hillary et al. (Bayesian penalised regression). (Table S8). List of
concordant SNPs identified by linear model and Bayesian penalised re-
gression and whether they have been previously identified as eQTLs.
(Table S9). Bayesian tests of colocalisation for cis pQTLs and cis eQTLs.
(Table S10). Sherlock algorithm: Genes whose expression are putatively
associated with circulating inflammatory proteins that harbour pQTLs.
(Table S11). CpGs associated with inflammatory protein biomarkers as
identified by Bayesian model (Bayesian model; Posterior Inclusion Prob-
ability > 95%). (Table S12). CpGs associated with inflammatory protein
biomarkers as identified by linear model (limma) at P < 5.14 × 10− 10.
(Table S13). CpGs associated with inflammatory protein biomarkers as
identified by mixed linear model (OSCA) at P < 5.14 × 10− 10. (Table S14).
Estimate of variance explained for blood protein levels by DNA methyla-
tion as well as proportion of explained attributable to different prior mix-
tures - BayesR+. (Table S15). Comparison of variance in protein levels
explained by genome-wide DNA methylation data by mixed linear model
(OSCA) and Bayesian penalised regression model (BayesR+). (Table S16).
Variance in circulating inflammatory protein biomarker levels explained
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by common genetic and methylation data (joint and conditional esti-
mates from BayesR+). Ordered by combined variance explained by gen-
etic and epigenetic data - smallest to largest. Significant results from t-
tests comparing distributions for variance explained by methylation or
genetics alone versus combined estimate are emboldened. (Table S17).
Genetic and epigenetic factors identified by BayesR+ when conditioning
on all SNPs and CpGs together. (Table S18). Mendelian Randomisation
analyses to assess whether proteins with concordantly identified genetic
signals are causally associated with Alzheimer’s disease risk. (Table S19).
Additional file 3. Details of Supplementary Methods. Contains
information for the following data: Conditional and joint analysis from
ordinary least squares GWAS on protein levels; Sherlock: identifying genes
whose expression associates with inflammatory biomarkers; GWAS and
EWAS of CCL11 levels – incorporating smoking status as a covariate;
Replication of previous pQTLs and protein associated-CpG sites; BayesR+
combined analysis – GWAS and EWAS modelled together; Evaluating
causal associations between blood inflammatory proteins and Alzheimer’s
risk.
Additional file 4: Supplementary Figures. Correlation between the
13 proteins with significant pQTLs as identified by ordinary least squares
and Bayesian penalised regression. (Figure S1). Correlation between
heritability estimates for circulating inflammatory protein biomarkers from
present study and that of Ahsan et al. The protein with the greatest
discordance between studies (MMP-1) is annotated. (Figure S2).
Correlation between the 3 proteins with significant CpG associations as
identified across ordinary least squares model, mixed model and Bayesian
penalised regression approaches. (Figure S3). Tissue-specific expression
of genes annotated to CpGs associated with CCL11 levels at P < 1 × 10− 5.
Differential expression was observed in kidney, adipose and breast tissue.
(Figure S4). Tissue-specific expression of genes annotated to CpGs asso-
ciated with IL18R1 levels at P < 1 × 10− 5. Differential expression was ob-
served in pancreatic, hippocampal and substantia nigra tissue. (Figure
S5). Tissue-specific expression of genes annotated to CpGs associated
with CXCL9 levels at P < 1 × 10–5. No tissue-specific expression was ob-
served. (Figure S6). Miami plot for IL18R1 which exhibited both
genome-wide significant SNP and genome-wide significant CpG associa-
tions. The top half of the plot (skyline) shows the results from the GWAS
on protein levels, whereas the bottom half (waterfront) shows the results
from the EWAS. IL18R1 (chromosome 2: 102,311,529-102,398,775). (Figure
S7).
Additional file 5. Variance in circulating protein levels explained by
common genetic and methylation data together.
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